Mean time in range for intravitreal aflibercept, bevacizumab, and ranibizumab according to BCVA thresholds, and responder analysis.
Mean time in range with intravitreal aflibercept, bevacizumab, and ranibizumab according to BCVA threshold in the Day 0–364 analysis (In the Day 0–364 responder analysis, using a BCVA letter score threshold of ≥69 (approximate Snellen equivalent 20/40), 68% of participants treated with IVT-AFL had a time in range of ≥80% (i.e. for 41.6 weeks over Year 1), compared with 60% of participants treated with IVT-RAN and 55% treated with IVT-BEV (Fig. 